Sarepta Therapeutics, Inc. (SRPT)
NASDAQ: SRPT · Real-Time Price · USD
110.51
-0.35 (-0.32%)
Nov 21, 2024, 2:24 PM EST - Market open
Sarepta Therapeutics Employees
Sarepta Therapeutics had 1,314 employees as of December 31, 2023. The number of employees increased by 152 or 13.08% compared to the previous year.
Employees
1,314
Change (1Y)
152
Growth (1Y)
13.08%
Revenue / Employee
$1,248,362
Profits / Employee
$92,728
Market Cap
10.56B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 1,314 | 152 | 13.08% |
Dec 31, 2022 | 1,162 | 322 | 38.33% |
Dec 31, 2021 | 840 | -26 | -3.00% |
Dec 31, 2020 | 866 | 123 | 16.55% |
Dec 31, 2019 | 743 | 244 | 48.90% |
Dec 31, 2018 | 499 | 244 | 95.69% |
Dec 31, 2017 | 255 | 58 | 29.44% |
Dec 31, 2016 | 197 | -73 | -27.04% |
Dec 31, 2015 | 270 | 66 | 32.35% |
Dec 31, 2014 | 204 | 58 | 39.73% |
Dec 31, 2013 | 146 | 43 | 41.75% |
Dec 31, 2012 | 103 | 5 | 5.10% |
Dec 31, 2011 | 98 | 0 | - |
Dec 31, 2010 | 98 | 35 | 55.56% |
Dec 31, 2009 | 63 | -20 | -24.10% |
Dec 31, 2008 | 83 | -42 | -33.60% |
Dec 31, 2007 | 125 | 8 | 6.84% |
Dec 31, 2006 | 117 | -6 | -4.88% |
Dec 31, 2005 | 123 | 11 | 9.82% |
Dec 31, 2004 | 112 | 6 | 5.66% |
Dec 31, 2003 | 106 | 17 | 19.10% |
Dec 31, 2002 | 89 | 4 | 4.71% |
Dec 31, 2001 | 85 | 14 | 19.72% |
Dec 31, 2000 | 71 | 15 | 26.79% |
Dec 31, 1999 | 56 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
Encompass Health | 37,761 |
Charles River Laboratories International | 21,800 |
Smith & Nephew | 19,081 |
Catalent | 17,800 |
AptarGroup | 13,800 |
Medpace Holdings | 5,900 |
Bio-Techne | 3,050 |
Exelixis | 1,310 |
SRPT News
- 12 days ago - Sarepta Therapeutics: BLA Filing Of SRP-9003 For LGMD Is The Next Step - Seeking Alpha
- 14 days ago - Sarepta Therapeutics, Inc. (SRPT) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 14 days ago - Sarepta Therapeutics Announces Third Quarter 2024 Financial Results and Recent Corporate Developments - Business Wire
- 20 days ago - Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 4 weeks ago - Sarepta Therapeutics to Announce Third Quarter 2024 Financial Results - Business Wire
- 4 weeks ago - This GE Vernova Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Benzinga
- 2 months ago - Sarepta Therapeutics to Present New Data from its Neuromuscular Portfolio at 2024 World Muscle Society Congress - Business Wire
- 2 months ago - Sarepta Therapeutics Muscles Up In DMD Race - Seeking Alpha